FDA Proposes Eight-Month Review of Priority Generics, Plans for Wave of Biosimilars

The FDA officially unveiled its recommendations for the second generation of user fee agreements covering generics and biosimilars, with commitments to eight-month reviews of priority generics.
Source: Drug Industry Daily